Janux Therapeutics CMO Dr. William Go departs; no impact on clinical timelines

Janux Therapeutics, Inc.

CMO William Go, M.D., Ph.D. departed June 23, 2026; company determined termination without Cause under severance plan.
Company initiated search for successor; existing clinical leadership team assumes interim responsibilities.
Departure not due to disagreement with company on operations, policies, or practices.
Transition does not affect development strategy, regulatory plans, or previously disclosed clinical timelines.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.